Hereditary Breast Cancer Guidelines-Based Panel, Sequencing and Deletion/Duplication
Germline analysis of moderate and high lifetime risk (>15%) hereditary breast cancer genes, including BRCA1 and BRCA2. For use in individuals with a personal or family history of hereditary breast cancer or other related cancers. Testing minors for adult-onset conditions is not recommended; testing will not be performed in minors without prior approval. For additional information, please contact an ARUP genetic counselor at 800-242-2787 ext. 2141.
To compare this test to other hereditary cancer panels, refer to the Hereditary Cancer Panel Comparison table.
New York DOH Approval Status
Lavender or pink (EDTA) or yellow (ACD solution A or B).
New York State Clients: Lavender (EDTA)
Transport 3 mL whole blood. (Min: 3 mL)
Serum or plasma; grossly hemolyzed or frozen specimens; saliva; buccal brush or swab, FFPE tissue.
Ambient: 72 hours; Refrigerated: 1 week; Frozen: Unacceptable
New York State Clients: Ambient: 48 hours; Refrigerated: 2 weeks; Frozen: Unacceptable
Massively Parallel Sequencing/Sequencing
Refer to report.
Laboratory Developed Test (LDT)
GENES TESTED: ATM; BARD1; BRCA1*; BRCA2; CDH1*; CHEK2*; NF1; PALB2; PTEN*; STK11; TP53
*One or more exons are not covered by sequencing and/or deletion/duplication analysis for the indicated gene; see Additional Technical Information.
81408; 81479; 81162; 81406; 81307; 81321; 81323; 81404; 81405; 81351
|Component Test Code*||Component Chart Name||LOINC|
- Cowden syndrome
- HBOC syndrome
- Hereditary diffuse gastric cancer (HDGC)
- Li-Fraumeni syndrome (LFS)
- Lynch syndrome
- Neurofibromatosis type 1
- Peutz-Jegher syndrome (PJS)
- PTEN hamartoma tumor syndrome